Last reviewed · How we verify
Live attenuated herpes zoster vaccine
Live attenuated herpes zoster vaccine is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 1 development.
At a glance
| Generic name | Live attenuated herpes zoster vaccine |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site erythema
- Pyrexia
- Irritability
- Somnolence
- Decreased appetite
- Injection site pain
- Injection site swelling
- Upper respiratory tract infection
- Rash
- Nasopharyngitis
- Cough
- Pain
Key clinical trials
- Second Dose of Varicella Vaccine in Healthy Children (PHASE3)
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept (PHASE2)
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion) (PHASE4)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Live attenuated herpes zoster vaccine CI brief — competitive landscape report
- Live attenuated herpes zoster vaccine updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Live attenuated herpes zoster vaccine
What is Live attenuated herpes zoster vaccine?
Live attenuated herpes zoster vaccine is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID).
Who makes Live attenuated herpes zoster vaccine?
Live attenuated herpes zoster vaccine is developed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).
What development phase is Live attenuated herpes zoster vaccine in?
Live attenuated herpes zoster vaccine is in Phase 1.
What are the side effects of Live attenuated herpes zoster vaccine?
Common side effects of Live attenuated herpes zoster vaccine include Injection site erythema, Pyrexia, Irritability, Somnolence, Decreased appetite, Injection site pain.